Trestle Biotherapeutics

Kidney disease impacts 850 million people worldwide, 37 million in the United States. There are only two treatment options for people who progress to kidney failure – a rare kidney transplant or dialysis. While dialysis is a life-saving and essential treatment for more than 550,000 Americans, there have been no advances of treatment options for those with kidney failure since its advent nearly 60 years ago. And while dialysis sustains life, patients must endure constant medical risks of infection, vascular collapse, and personal tolls on quality of life.

Trestle is developing an implantable therapeutic tissue that will be delivered to patients suffering from end stage renal disease (ESRD). Our implantable bioengineered tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.